Tianlong's New Launch Gentier X3 Made its Appearance at Medlab Middle East 2024

February 09, 2024 12:00 AM AEDT | By Cision

Tianlong's New Launch Gentier X3 Made its Appearance at Medlab Middle East 2024 — Image source: Kalkine Media

Recent News

King River Resources (ASX:KRR): Tennant Creek Drilling Progress and 20...

Opec+ Output Surprise Impacts Crude Sector, ASX 200 and Global Markets...

ASX 200 slips as financials and energy stocks weigh down indexes

Wesfarmers (ASX:WES) Shares Reach Record High as ASX 200 Steadies Befo...

DUBAI, UAE, Feb. 8, 2024 /PRNewswire/ -- The 4-day Medlab Middle East 2024 at the Dubai World Trade Center came to an end successfully on February 8. MedLab is the largest exhibition of medical equipment in the Middle East region, attracting visitors worldwide to experience the academic atmosphere and technological innovation.

As a R&D enterprise specializing in genetic detection and molecular diagnostics for 27 years, Tianlong Technology is playing an active role in the international market. This time in Dubai, Tianlong joined hands with Shanghai Kehua Bio-engineering(KHB) and Focus Diagnostics, showcased the comprehensive solutions integrating immune diagnosis, biochemical diagnosis, molecular diagnosis and POCT on the exhibition.

On Medlab 2024, Tianlong announces its brand-new product - Gentier X3 Series Real-time PCR System, which innovates in flexibility and allows users to control three independent blocks in the same PCR system, gained popularity on the exhibition. With Gentier X3, maximum 3×32-well samples can be run in three different protocols on three independent thermal blocks simultaneously. With the powerful and efficient temperature control system, user-friendly operational designs, it can provide maximal reliability and efficiency for all your real-time PCR needs. A visitor from South Korea commented that this Gentier X3 is a very efficient PCR solution, saving time and budget for users conducting tests of multiple samples of small and medium capacity simultaneously.

At the exhibition, Tianlong's international team introduced the integrated product solutions and engaged in communication and negotiation with visitors, and had preliminary discussions on cooperation with customers from Russia, Morocco, Yemen, India, Iraq, and Egypt etc..

Tianlong's first exhibition in 2024 has successfully come to an end. In the future, Tianlong will continue to expand its commercial presence in key regions worldwide while contributing to the global health cause through advanced scientific and technological innovation.

About Tianlong

Tianlong is an innovative high-tech company specializing in genetic detection and molecular diagnostic products in China. Since its foundation in 1997, Tianlong has devoted itself to providing integrated PCR lab solutions for professionals worldwide. We have a wide range of products covering from devices to reagents, including nucleic acid extractors, real-time PCR systems, all-in-one molecular diagnosis systems, sample processing systems, liquid handling systems, and 300 kinds of compatible reagents. With NMPA, CE, and FDA listing, our products have been exported to more than 100 countries and regions worldwide and have greatly helped the prevention and control of epidemics such as COVID-19, SARS, Avian influenza, Ebola, Zika, and African swine fever.

For more information, please visit Tianlong's official website and its LinkedIn, Facebook, and Twitter pages.

For product or corporate information inquiries may be directed to [email protected].

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.